nach oben

Journal of Nephrology

Erschienen in:

01.08.2016 | Review

Markers for the progression of IgA nephropathy

verfasst von: Dita Maixnerova, Colin Reily, Qi Bian, Michaela Neprasova, Jan Novak, Vladimir Tesar

Erschienen in: Journal of Nephrology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, κ light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.

Moriyama T, Tanaka K, Iwasaki C et al (2014) Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS One 9:e91756CrossRefPubMedPubMedCentral

Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402–2414CrossRefPubMed

Cattran DC, Coppo R, Cook HT et al (2009) Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRefPubMed

Coppo R, Troyanov S, Camilla R et al (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927CrossRefPubMed

Feehally J, Floege J (2007) IgA nephropathy and Henoch-Schönlein nephritis. In: Feehally J, Floege J, Johnson RJ (ed) Comprehensive clinical nephrology, 3rd edn. Mosby, Philadelphia, pp 253–264

Kiryluk K, Li Y, Sanna-Cherchi S et al (2012) Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8:e1002765CrossRefPubMedPubMedCentral

Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196CrossRefPubMedPubMedCentral

Tomana M, Matousovic K, Julian BA et al (1997) Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509–516CrossRefPubMed

Tomana M, Novak J, Julian BA et al (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73–81CrossRefPubMedPubMedCentral

10.

Novak J, Raskova Kafkova L, Suzuki H et al (2011) IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant 26:3451–3457CrossRefPubMedPubMedCentral

11.

Maillard N, Wyatt RJ, Julian BA et al (2015) Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 26:1503–1512CrossRefPubMedPubMedCentral

12.

Schmitt R, Stahl AL, Al Olin et al (2014) The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol 193:317–326CrossRefPubMedPubMedCentral

13.

Daha MR, van Kooten C (2016) Role of complement in IgA nephropathy. J Nephrol 29:1–4CrossRefPubMed

14.

Suzuki H, Ohsawa I, Kodama F et al (2013) Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol 26:708–715CrossRefPubMed

15.

Lai KN, Leung JC, Chan LY et al (2008) Activation of podocytes by mesangial-derived TNF-α: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294:F945–F955CrossRefPubMed

16.

Maixnerova D, Bauerova L, Skibova J et al (2012) The retrospective analysis of 343 Czech patients with IgA nephropathy—one centre experience. Nephrol Dial Transplant 27:1492–1498CrossRefPubMed

17.

Reich HN, Troyanov S, Scholey JW et al (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183CrossRefPubMed

18.

Alamartine E, Sauron C, Laurent B et al (2011) The use of Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 6:2384–2388CrossRefPubMedPubMedCentral

19.

Berthoux F, Mohey H, Laurent B et al (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752–761CrossRefPubMedPubMedCentral

20.

Barbour SJ, Cattran DC, Espino-Hernandez G et al (2015) Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int 88:1392–1401CrossRefPubMed

21.

Barbour SJ, Reich HN (2012) Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 59:865–873CrossRefPubMed

22.

Coppo R, D’Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18:503–512PubMed

23.

Kaartinen K, Syrjanen J, Porsti I et al (2008) Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 23:1285–1290CrossRefPubMed

24.

Roberts IS, Cook HT et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556CrossRefPubMed

25.

Barbour SJ, Espino-Hernandez G, Reich HN et al (2016) The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 89:1671–1675

26.

Coppo R, Troyanov S, Bellur S et al (2014) Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86:828–836CrossRefPubMedPubMedCentral

27.

Bellur SS, Troyanov S, Cook HT et al (2011) Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 26:2533–2536CrossRefPubMed

28.

Wada Y, Ogata H, Takeshige Y et al (2013) Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol 17:73–82CrossRefPubMed

29.

Yanagawa H, Suzuki H, Suzuki Y et al (2014) A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS ONE 9:e98081CrossRefPubMedPubMedCentral

30.

Nakata J, Suzuki Y, Suzuki H et al (2014) Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One 9:e89707CrossRefPubMedPubMedCentral

31.

Suzuki H, Raska M, Yamada K et al (2014) Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem 289:5330–5339CrossRefPubMed

32.

Moldoveanu Z, Wyatt RJ, Lee J et al (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148–1154CrossRefPubMed

33.

Hastings MC, Moldoveanu Z, Julian BA et al (2010) Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 5:2069–2074CrossRefPubMedPubMedCentral

34.

Zhao N, Hou P, Lv J et al (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796CrossRefPubMedPubMedCentral

35.

Suzuki H, Kiryluk K, Novak J et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803CrossRefPubMedPubMedCentral

36.

Launay P, Grossetête B, Arcos-Fajardo M et al (2000) Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 191:1999–2009CrossRefPubMedPubMedCentral

37.

Berthelot L, Papista C, Maciel TT et al (2012) Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209:793–806CrossRefPubMedPubMedCentral

38.

Vuong MT, Hahn-Zoric M, Lundberg S et al (2010) Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78:1281–1287CrossRefPubMed

39.

Lechner SM, Papista C, Chemouny JM et al (2016) Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol 29:5–11CrossRefPubMed

40.

Delanghe SE, Speeckaert MM, Segers H et al (2013) Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schönlein purpura nephritis. Clin Biochem 46:591–597CrossRefPubMed

41.

Peters HP, Waanders F, Meijer E et al (2011) High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant 26:3581–3588CrossRefPubMed

42.

Peters HP, van den Brand JA, Wetzels JF (2009) Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy. Neth J Med 67:54–61PubMed

43.

Shimozato S, Hiki Y, Odani H, Takahashi K, Yamamoto K, Sugiyama S (2008) Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transplant 23(6):1931–1939. doi:10.1093/ndt/gfm913 CrossRefPubMed

44.

Yasutake J, Suzuki Y, Suzuki H et al (2015) Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30:1315–1321CrossRefPubMedPubMedCentral

45.

Berthoux F, Suzuki H, Thibaudin L et al (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587CrossRefPubMedPubMedCentral

46.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119(6):1668–1677. doi:10.1172/JCI38468 PubMedPubMedCentral

47.

Hastings MC, Moldoveanu Z, Suzuki H et al (2013) Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn 7:615–627CrossRefPubMedPubMedCentral

48.

Caliskan Y, Kiryluk K (2014) Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis 21:205–216CrossRefPubMedPubMedCentral

49.

Szeto CC, Li PK (2014) Micro RNAs in IgA nephropathy. Nat Rev Nephrol 10:249–256CrossRefPubMed

50.

Serino G, Sallustio F, Cox SN et al (2012) Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 23:814–824CrossRefPubMedPubMedCentral

51.

Wang N, Bu R, Duan Z et al (2015) Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy. PeerJ 3:e990. doi:10.7717/peerj.990 CrossRefPubMedPubMedCentral

52.

Xing Li-Na, Wang H, Yin PH et al (2014) Reduced mir-29b-3p expression up-regulate CDK6 and contributes to IgA nephropathy. Int J Clin Exp Med 7:5275–5281PubMedPubMedCentral

53.

Bao H, Chen H, Zhu X et al (2014) MiR 223 downregulation promotes glomerular endothelial cell activation by upregulating importin α4 and α5 in IgA nephropathy. Kidney Int 85:624–635CrossRefPubMed

54.

Berthelot L, Robert T, Vuiblet V et al (2015) Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88:815–822CrossRefPubMed

55.

Xu PC, Wei L, Shang WY et al (2014) Urinary kidney injury molecule-1 is related to pathologic involvement in IgA nephropathy with normotension, normal renal function and mild proteinuria. BMC Nephrol 7:107CrossRef

56.

Ranieri E, Gesualdo L, Petrarulo F et al (1996) Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50:1990–2001CrossRefPubMed

57.

Torres DD, Rossini M, Manno C et al (2008) The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73:327–333CrossRefPubMed

58.

Aizawa T, Imaizumi T, Tsuruga K et al (2013) Urinary fractalkine and monocyte chemoattractant protein-1 as possible predictors of disease activity of childhood glomerulonephritis. Tohoku J Exp Med 231:265–270CrossRefPubMed

59.

Rocchetti MT, Papale M, d’Apollo AM et al (2013) Association of urinary laminin G-like 3 and free κ light chains with disease activity and histological injury in IgA nephropathy. Clin J Am Soc Nephrol 8:1115–1125CrossRefPubMedPubMedCentral

60.

Wu J, Wang N, Wang J et al (2010) Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom 24:1971–1978CrossRefPubMed

61.

Candiano G, Musante L, Bruschi M et al (2006) Repetitive fragmentation products of albumin and α1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 17:3139–3148CrossRefPubMed

62.

Asao R, Asanuma K, Kodama F et al (2012) Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol 7:1385–1393CrossRefPubMedPubMedCentral

63.

Good DM, Zürbig P, Argiles A et al (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9:2424–2437CrossRefPubMedPubMedCentral

64.

Liu LL, Jiang Y, Wang LN et al (2012) Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol 169:148–155CrossRefPubMedPubMedCentral

65.

Sogabe A, Uto H, Kanmura S et al (2013) Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy. Int J Mol Med 32:307–314PubMed

66.

Gharavi AG, Kiryluk K, Choi M et al (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327CrossRefPubMedPubMedCentral

67.

Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46(11):1187–1196CrossRefPubMedPubMedCentral

68.

Li M, Foo JN, Wang JQ et al (2015) Identification of new susceptibility loci for IgA nephropathy in Han Chinese. Nat Commun 6:7270. doi:10.1038/ncomms8270 CrossRefPubMedPubMedCentral

Titel: Markers for the progression of IgA nephropathy
verfasst von: Dita Maixnerova
Colin Reily
Qi Bian
Michaela Neprasova
Jan Novak
Vladimir Tesar
Publikationsdatum: 01.08.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 4/2016
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0299-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Treatment of IgA nephropathy with renal insufficiency

Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms

IgG4-related nephropathy

Remission and withdrawal of therapy in lupus nephritis

Focal segmental glomerular sclerosis: do not overlook the role of immune response